<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Pharmacol Rep</journal-id><journal-id journal-id-type="iso-abbrev">Curr Pharmacol Rep</journal-id><journal-title-group><journal-title>Current Pharmacology Reports</journal-title></journal-title-group><issn pub-type="epub">2198-641X</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7921287</article-id><article-id pub-id-type="publisher-id">254</article-id><article-id pub-id-type="doi">10.1007/s40495-021-00254-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Natural Products: From Chemistry to Pharmacology (C Ho, Section Editor)</subject></subj-group></article-categories><title-group><article-title>Determination of Potential Drug Candidate Molecules of the <italic>Hypericum perforatum</italic> for COVID-19 Treatment</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Yal&#x000e7;&#x00131;n</surname><given-names>Serap</given-names></name><address><email>syalcin@ahievran.edu.tr</email><email>serapyalcin1982@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yal&#x000e7;&#x00131;nkaya</surname><given-names>Seda</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ercan</surname><given-names>Fahriye</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.411224.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0399 5752</institution-id><institution>Department of Molecular Biology and Genetics, Faculty of Art and Sciences, </institution><institution>K&#x00131;rsehir Ahi Evran University, </institution></institution-wrap>40100 K&#x00131;rsehir, Turkey </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.45978.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0527 3171</institution-id><institution>Department of Food Engineering, Faculty of Engineering, </institution><institution>S&#x000fc;leyman Demirel University, </institution></institution-wrap>Isparta, Turkey </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.411224.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0399 5752</institution-id><institution>Department of Plant Protection, Faculty of Agriculture, </institution><institution>K&#x00131;rsehir Ahi Evran University, </institution></institution-wrap>K&#x00131;r&#x0015f;ehir, Turkey </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>3</month><year>2021</year></pub-date><fpage>1</fpage><lpage>7</lpage><history><date date-type="accepted"><day>7</day><month>2</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The novel human coronavirus was firstly emerged in December 2019 in Wuhan, China, and has spread rapidly around the world. There is no known specific effective treatment of COVID-19. The most commonly used agents against this disease both in Turkey and around the world include chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir, and remdesivir. In the study, we investigated the drug potential of molecules that the components of an important medicinal plant <italic>Hypericum perforatum</italic> by using molecular docking and drug possibility properties of these molecules. The molecular docking results showed that the most stable complex was obtained with COVID-19 main protease and hypericin/isohypericin ligands with &#x02212; 11 kcal/mol binding energy. Furthermore, ADMET, drug-likeness features of compounds of <italic>H. perforatum</italic> were investigated using the rules of Lipinski, Veber, and Ghose. According to the results obtained, it has been shown that <italic>H. perforatum</italic> has the potential to be an effective drug in the COVID-19 pandemic. In the next stage, it is necessary to carry out the clinically necessary reliability studies of these components. It is thought that it can be used for the treatment of COVID-19 if our molecular docking results are found to be in high correlation with clinical studies.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s40495-021-00254-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>COVID-19</kwd><kwd><italic>Hypericum perforatum</italic></kwd><kwd>Molecular docking</kwd><kwd>ADMET</kwd><kwd>Drug-likeness drug</kwd></kwd-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2"><italic>Hypericum perforatum</italic> is commonly known as St. John&#x02019;s wort around the world and in Turkey is known as yellow cantaron and blood grass. This species is highly important and remarkable because of its pharmacological effects like antidepressant, antiviral, and antibacterial properties. These features made it the most studied species of <italic>Hypericum</italic> [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par3">Several studies of <italic>H. perforatum</italic> introduced that the chemical components of plant (naftodiantrone compounds (hypericin, psodohypericin), fluoroglusinols (hyperforin), flavonoids (hyperositis, quercetin), biflavones (biapigenin, amentoflavones) phenolic acids, (ferulic acid, caffeic acid), proanthocyanidins, and essential oils) have provided its pharmacological effects [<xref ref-type="bibr" rid="CR2">2</xref>]. There are also studies showing that it has potent cytotoxic and proapoptotic effects against tumor cell lines and inhibits tumor-induced angiogenesis [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par4">These medicinal plant extracts include complex phytochemicals, and the complete molecular characteristics of these pharmacologically important chemicals are still unknown. However, napthodianthrones are a considerable compound of <italic>H. perforatum</italic> extracts, and hypericin is the best-characterized member of this class. Hypericin is one of the main components of <italic>H. perforatum</italic>. It can be extracted from the plant or chemically synthesized and has powerful cytotoxic and proapoptotic effects on cancer cells [<xref ref-type="bibr" rid="CR5">5</xref>]. The molecular mechanism of this component is not known, but previous studies have reported the different cellular pathways related to survival, necrosis, or apoptosis of the cell [<xref ref-type="bibr" rid="CR6">6</xref>]. Therewithal, further studies are needed to reveal the action of these compounds.</p><p id="Par5">COVID-19 is a new strain of coronavirus that affects primarily aging humans with especially dyspnea. Alveolar-interstitial pneumonia develops in 20% of patients with acute respiratory distress syndrome. This virus spreads rapidly worldwide, and the World Health Organization (WHO) has announced it as a pandemic disease [<xref ref-type="bibr" rid="CR7">7</xref>]. There is no specific treatment known so far. Thus, new approaches to drug design and discovery can be used as a promising tool for the discovery of some therapeutic drug candidates against COVID-19. In this sense, molecular docking has become a promising and useful tool for drug design and development and attracts researchers&#x02019; attention. With this useful tool, we tried to reveal the binding potential of the target protein and the ligands with drug potential [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par6">Many drugs, including chloroquine, remdesivir, and hydroxychloroquine, have been shown to be effective against COVID-19 [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Most of these drugs are HIV protease inhibitors. Chloroquine and hydroxychloroquine are thought to cause changes in glycolysis transferases in the vesicles of the endoplasmic reticulum or trans-Golgi complex at low pH [<xref ref-type="bibr" rid="CR12">12</xref>]. In the study, we have performed a docking procedure with COVID-19 (PDB ID: 6LU7) and main components of <italic>H. perforatum</italic> as a ligand.</p></sec><sec id="Sec2"><title>Materials and Methods</title><p id="Par7">Molecular docking calculations were performed in Autodock Vina software [<xref ref-type="bibr" rid="CR13">13</xref>]. The water molecules and cofactors were removed from the protein to clearly see the protein-ligand interaction. COVID-19 main protease [<xref ref-type="bibr" rid="CR14">14</xref>] was used as a protein, and the structure of this protein was freely available from the RCSB Protein Data Bank as a 3D theoretical model (PDB ID: 6LU7) (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/6LU7">https://www.rcsb.org/structure/6LU7</ext-link>). Ligands used in the study and their properties are given in Table <xref rid="Tab1" ref-type="table">1</xref>. Ligands were obtained from PubChem (<ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/">https://pubchem.ncbi.nlm.nih.gov/</ext-link>). Protein-ligand interactions were screened by Molegro Molecular Viewer 2.5 (Molegro Molecular viewer free software) (<ext-link ext-link-type="uri" xlink:href="http://www.molegro.com">http://www.molegro.com</ext-link>) [<xref ref-type="bibr" rid="CR15">15</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Ligands used in the study and their properties</p></caption><graphic position="anchor" xlink:href="40495_2021_254_Tab1a_HTML" id="d32e315"/><graphic position="anchor" xlink:href="40495_2021_254_Tab1b_HTML" id="d32e316"/><graphic position="anchor" xlink:href="40495_2021_254_Tab1c_HTML" id="d32e317"/><graphic position="anchor" xlink:href="40495_2021_254_Tab1d_HTML" id="d32e318"/></table-wrap></p><p id="Par8">The binding potential of chloroquine and hydroxychloroquine has been reviewed as a control ligand. 2D structure of the ligands was converted to energy-minimized 3D structure. The binding energy results calculated by Vina are presented in Table <xref rid="Tab2" ref-type="table">2</xref>. All protein and ligands were validated before performing the in silico computations [<xref ref-type="bibr" rid="CR16">16</xref>]. Protein and ligand interactions can be observed in Figs. 1&#x02013;19 (Supplementary file <xref rid="MOESM1" ref-type="media">1</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Target protein and drug candidate molecules (ligands) molecular docking results</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Ligands</th><th>Binding energy (kcal/mol)</th><th>H bound and a.a. side</th></tr></thead><tbody><tr><td>Chloroquine</td><td>&#x02212; 5.6 kcal/mol</td><td>1 (Trp 218)</td></tr><tr><td>Hydroxychloroquine</td><td>&#x02212; 7.0 kcal/mol</td><td>0</td></tr><tr><td>Hypericin</td><td>&#x02212; 11 kcal/mol</td><td>6 (Asp 197x2; Lys 137; Leu 287x3)</td></tr><tr><td>Protopseudohypericin</td><td>&#x02212; 9.9 kcal/mol</td><td>5 (Tyr 239x2; Leu 271, Leu 272; Thr 199)</td></tr><tr><td>Hyperocide</td><td>&#x02212; 9.5 kcal/mol</td><td>5 (Asn274; Glu 270; Arg 279; Asn 277x2)</td></tr><tr><td>Cryptochlorogenic acid</td><td>&#x02212; 8.1 kcal/mol</td><td>6 (Gly 183; Phe 181; Arg 188; Glu 55; Arg 40x2)</td></tr><tr><td>Isohypericin</td><td>&#x02212; 11.0 kcal/mol</td><td>4 (Asp 197x2; Lys 137; Tyr 239)</td></tr><tr><td>Mangiferin</td><td>&#x02212; 9.7 kcal/mol</td><td>6 (Thr 199; Asp 289; Leu 287; Tyr 239x2; Leu 271)</td></tr><tr><td>Neochlorogenic acid</td><td>&#x02212; 8.6 kcal/mol</td><td>2 (Thr 292; Thr 111)</td></tr><tr><td>Catechin</td><td>&#x02212; 7.4 kcal/mol</td><td>4 (Leu 287; Thr 199; Asp 197; Tyr 237)</td></tr><tr><td>Protocatehuic acid</td><td>&#x02212; 5.9 kcal/mol</td><td>4 (Asn 277x2; Arg 279; Asn 221)</td></tr><tr><td>2-Methyldecane</td><td>&#x02212; 5.0 kcal/mol</td><td>0</td></tr><tr><td>Pseudohypericin</td><td>&#x02212; 10.7 kcal/mol</td><td>5(Thr 199, Tyr 237, Leu 272, Leu 287x2)</td></tr><tr><td>Protohypericin</td><td>&#x02212; 9.7 kcal/mol</td><td>5 (Asn 238; Thr 199; Tyr 239x2; Leu 271; Leu 272)</td></tr><tr><td>Adhyperforin</td><td>&#x02212; 8.8 kcal/mol</td><td>1 (Leu 287)</td></tr><tr><td>Hiperforine</td><td>&#x02212; 7.9 kcal/mol</td><td>2 (Arg 279; Asn 274)</td></tr><tr><td>Miquelianin</td><td>&#x02212; 9.8 kcal/mol</td><td>3 (Tyr 239; Leu 287; Thr 199)</td></tr><tr><td>Biapigenin</td><td>&#x02212; 9.8 kcal/mol</td><td>6 (Leu 271; Leu 287x2; Tyr 239; Thr 199; Asn 238)</td></tr><tr><td>Guaijaverin</td><td>&#x02212; 9.3 kcal/mol</td><td>5 (Asn 274; Glu 270; Arg 279; Asn 277x2)</td></tr><tr><td>Epicatechin</td><td>&#x02212; 7.9 kcal/mol</td><td>5 (Tyr 237; Thr 199; Asp 289; Lys 137;Tyr 239)</td></tr><tr><td>Norathyriol</td><td>&#x02212; 7.1 kcal/mol</td><td>3 (Arg 105; Gln 110; Thr 111)</td></tr><tr><td>Beta-Ocimene</td><td>&#x02212; 5.2 kcal/mol</td><td>0</td></tr><tr><td>2-Methyloctane</td><td>&#x02212; 4.3 kcal/mol</td><td>0</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec3"><title>Drug Likeness and ADMET Prediction for the Components</title><p id="Par9">Currently, computer-based ADMET analyses are gaining for drug discovery [<xref ref-type="bibr" rid="CR17">17</xref>]. ADMET analyses are used to decide the pharmacological structure from the perspective of drug discovery (<ext-link ext-link-type="uri" xlink:href="http://biosig.unimelb.edu.au/pkcsm/prediction">http://biosig.unimelb.edu.au/pkcsm/prediction</ext-link>). Pharmacokinetics and drug-likeness prediction of drug candidate molecule(s) were performed by online tools SwissADME (<ext-link ext-link-type="uri" xlink:href="http://www.sib.swiss">http://www.sib.swiss</ext-link>) (<ext-link ext-link-type="uri" xlink:href="http://www.swissadme.ch/index.php">http://www.swissadme.ch/index.php</ext-link>) [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>] and admetSAR (<ext-link ext-link-type="uri" xlink:href="http://lmmd.ecust.edu.cn/admetsar2/">http://lmmd.ecust.edu.cn/admetsar2/</ext-link>) [<xref ref-type="bibr" rid="CR20">20</xref>]. In addition, these toxicological predictions have applied to Lipinski, Ghose, and Veber rules and bioavailability scores [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>].</p></sec><sec id="Sec4"><title>Results and Discussion</title><p id="Par10">Molecular docking results obtained from this study indicated a strong interaction between COVID-19 main protease and potential drug candidates. The binding strength was defined by use of scoring function based on the Lamarckian generic algorithm. The binding free energy may include electrostatic, hydrogen bonding, and van der Waals interactions [<xref ref-type="bibr" rid="CR14">14</xref>]. The least binding energy refers to the most stable binding between protein and the ligand. According to these results, the best stable binding score was obtained between tested protein and hypericin/isohypericin ligands with same score (&#x02212; 11 kcal/mol binding energy). All of the docked structures were visualized in Molegro Molecular viewer (free academic).</p><p id="Par11">In this study, human intestinal absorption, aqueous solubility levels, BBB penetration levels, CYP inhibition (CYP2D6, CYP3A4, CYP1A2, CYP2C19, CYP2C6, CYP2D6), hepatotoxicity, AMES toxicity, max. tolerated, dose etc. of compounds of <italic>H. perforatum</italic> were analyzed by prediction models. ADMET (absorption, distribution, metabolism, excretion, toxicity) analysis shows that compounds predicted good human intestinal absorption and no hepatotoxicity (Supplementary file <xref rid="MOESM2" ref-type="media">2</xref>).</p><p id="Par12">Drug-likeness can be characterized as a complex balance of different structural properties that determines whether a compound is a drug. These features are mainly lipophilicity, hydrogen bonding properties, molecule size, pharmacophoric features, and many others [<xref ref-type="bibr" rid="CR24">24</xref>]. In addition, drug-likeness results of compounds are shown in Table <xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Drug-likeness results of compounds</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Ligand</th><th colspan="3">Drug-likeness</th><th rowspan="2">Bioavailability score</th></tr><tr><th>Lipinski</th><th>Ghose</th><th>Veber</th></tr></thead><tbody><tr><td>Hypericin</td><td>No; 2 violations: MW &#x0003e; 500, NHorOH &#x0003e; 5</td><td>No; 3 violations: MW &#x0003e; 480, WLOGP &#x0003e; 5.6, MR &#x0003e; 130</td><td>No; 1 violation: TPSA &#x0003e; 140</td><td>0,17</td></tr><tr><td>Pseudohypericin</td><td>No; 2 violations: MW &#x0003e; 500, NHorOH &#x0003e; 5</td><td>No; 2 violations: MW &#x0003e; 480, MR &#x0003e; 130</td><td>No; 1 violation: TPSA &#x0003e; 140</td><td>0,17</td></tr><tr><td>Protopseudohypericin</td><td>No; 2 violations: MW &#x0003e; 500, NHorOH &#x0003e; 5</td><td>No; 2 violations: MW &#x0003e; 480, MR &#x0003e; 130</td><td>No; 1 violation: TPSA &#x0003e; 140</td><td>0,17</td></tr><tr><td>Protohypericin</td><td>No; 2 violations: MW &#x0003e; 500, NHorOH &#x0003e; 5</td><td>No; 2 violations: MW &#x0003e; 480, MR &#x0003e; 130</td><td>No; 1 violation: TPSA &#x0003e; 140</td><td>0,17</td></tr><tr><td>Hyperocide</td><td>No; 2 violations: NorO &#x0003e; 10, NHorOH &#x0003e; 5</td><td>No; 1 violation: WLOGP &#x0003c; &#x02212; 0.4</td><td>No; 1 violation: TPSA &#x0003e; 140</td><td>0,17</td></tr><tr><td>Adhyperforin</td><td>No; 2 violations: MW &#x0003e; 500, MLOGP &#x0003e; 4.15</td><td>No; 4 violations: MW &#x0003e; 480, WLOGP &#x0003e; 5.6, MR &#x0003e; 130, #atoms &#x0003e; 70</td><td>No; 1 violation: rotors &#x0003e; 10</td><td>0,56</td></tr><tr><td>Cryptochlorogenic acid</td><td>Yes; 1 violation: NHorOH &#x0003e; 5</td><td>No; 1 violation: WLOGP &#x0003c; &#x02212; 0.4</td><td>No; 1 violation: TPSA &#x0003e; 140</td><td>0,11</td></tr><tr><td>Hiperforine</td><td>No; 2 violations: MW &#x0003e; 500, MLOGP &#x0003e; 4.15</td><td>No; 4 violations: MW &#x0003e; 480, WLOGP &#x0003e; 5.6, MR &#x0003e; 130, #atoms &#x0003e; 70</td><td>No; 1 violation: rotors &#x0003e; 10</td><td>0,56</td></tr><tr><td>Isohypericin</td><td>No; 2 violations: MW &#x0003e; 500, NHorOH &#x0003e; 5</td><td>No; 3 violations: MW &#x0003e; 480, WLOGP &#x0003e; 5.6, MR &#x0003e; 130</td><td>No; 1 violation: TPSA &#x0003e; 140</td><td>0,17</td></tr><tr><td>Miquelianin</td><td>No; 2 violations: NorO&#x0003e;10, NHorOH&#x0003e;5</td><td>No; 1 violation: WLOGP &#x0003c; &#x02212; 0.4</td><td>No; 1 violation: TPSA &#x0003e; 140</td><td>0,11</td></tr><tr><td>Biapigenin</td><td>No; 2 violations: MW &#x0003e; 500, NHorOH &#x0003e; 5</td><td>No; 2 violations: MW &#x0003e; 480, MR &#x0003e; 130</td><td>No; 1 violation: TPSA &#x0003e; 140</td><td>0,17</td></tr><tr><td>Mangiferin</td><td>No; 2 violations: NorO &#x0003e; 10, NHorOH &#x0003e; 5</td><td>No; 1 violation: WLOGP &#x0003c; &#x02212; 0.4</td><td>No; 1 violation: TPSA &#x0003e; 140</td><td>0,17</td></tr><tr><td>Guaijaverin</td><td>No; 2 violations: NorO &#x0003e; 10, NHorOH &#x0003e; 5</td><td>Yes</td><td>No; 1 violation: TPSA &#x0003e; 140</td><td>0,17</td></tr><tr><td>Neochlorogenic acid</td><td>Yes; 1 violation: NHorOH &#x0003e; 5</td><td>No; 1 violation: WLOGP &#x0003c; &#x02212; 0.4</td><td>No; 1 violation: TPSA &#x0003e; 140</td><td>0,11</td></tr><tr><td>Epicatechin</td><td>Yes</td><td>Yes</td><td>Yes</td><td>0,55</td></tr><tr><td>Catechin</td><td>Yes</td><td>Yes</td><td>Yes</td><td>0,55</td></tr><tr><td>Norathyriol</td><td>Yes</td><td>Yes</td><td>Yes</td><td>0,55</td></tr><tr><td>Protocatehuic acid</td><td>Yes</td><td>No; 3 violations: MW&#x0003c;160, MR&#x0003c;40, #atoms &#x0003c; 20</td><td>Yes</td><td>0,56</td></tr><tr><td>Beta-Ocimene</td><td>Yes</td><td>No; 1 violation: MW &#x0003c; 160</td><td>Yes</td><td>0,55</td></tr><tr><td>2-Methyldecane</td><td>Yes; 1 violation: MLOGP &#x0003e; 4.15</td><td>No; 1 violation: MW &#x0003c; 160</td><td>Yes</td><td>0,55</td></tr><tr><td>2-Methyloctane</td><td>Yes; 1 violation: MLOGP &#x0003e; 4.15</td><td>No; 1 violation: MW &#x0003c; 160</td><td>Yes</td><td>0,55</td></tr></tbody></table></table-wrap></p><p id="Par13">According to Lipinski&#x02019;s rule (Pfizer&#x02019;s rule, Lipinski&#x02019;s rule of five, RO5), the active drug has no more than one violation of the following properties including molecular weight (MW) &#x02264; 500, LogP &#x02264; 5, hydrogen bond acceptors &#x02264; 10, and hydrogen bond donors &#x02264; 5 [<xref ref-type="bibr" rid="CR21">21</xref>]. According to Veber rules, the active drug has total hydrogen bonds &#x02264; 12, rotatable bonds &#x02264; 10, and polar surface area (PSA) &#x02264; 140 tend to have oral bioavailability &#x02265; 20% [<xref ref-type="bibr" rid="CR22">22</xref>]. According to Ghose rules, active drug has Log P(&#x02212; 0.4~5.6), MR (molar refractivity (40~150), MW (160~480), number of atoms (20~70), and PSA &#x0003c; 140 [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par14">Based on the drug-likeness analysis, guaijaverin, epicatechin, catechin, norathyriol, protocatechuic acid, beta-ocimene, 2-methyldecane, and 2-methyloctane were found in accordance with the Lipinski&#x02019;s, Veber&#x02019;s, or Ghose&#x02019;s rule. However, Lipinski&#x02019;s rule of five may not apply to natural compounds. The only half of all FDA-approved small-molecule drugs are both used and compatible with the &#x0201c;rule of five&#x0201d; [<xref ref-type="bibr" rid="CR25">25</xref>]. Therefore, it has the potential to be used as a medicine in other molecules.</p></sec><sec id="Sec5"><title>Conclusion</title><p id="Par15"><italic>Hypericum</italic> sp., used for many years as a medicinal plant for different treatments, has recently become popular with research for its different properties. This medicinal plant has long been used due to the beneficial effects it has on human health [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>]. In our research, the possibility of this useful plant being used against COVID-19, which our country and other countries in the world have been fighting for a long time, has been investigated. Based on the results, it was concluded that <italic>H. perforatum</italic> could be effective against COVID-19 and it is hypothesized that compounds may be screened to in vitro and in vivo experimental analyses to indicate its inhibitory potency.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec6"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40495_2021_254_MOESM1_ESM.docx"><label>ESM 1</label><caption><p>(DOCX 16762 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="40495_2021_254_MOESM2_ESM.docx"><label>ESM 2</label><caption><p>(DOCX 100 kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p>This article is part of the Topical Collection on <italic>Natural Products: From Chemistry to Pharmacology</italic></p></fn><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>LA</given-names></name><name><surname>Phillipson</surname><given-names>JD</given-names></name></person-group><article-title>St John&#x02019;s wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties</article-title><source>J Pharm Pharmacol</source><year>2001</year><volume>53</volume><issue>5</issue><fpage>583</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1211/0022357011775910</pub-id><?supplied-pmid 11370698?><pub-id pub-id-type="pmid">11370698</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Hostettmann K, Wolfender JL. St. John's Wort and its Active Principles in Depression and Anxiety. <italic>Phytochemistry</italic>. 2005:5&#x02013;20. 10.1007/3-7643-7338-5_2.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Momekov</surname><given-names>G</given-names></name><name><surname>Ferdinandov</surname><given-names>D</given-names></name><name><surname>Zheleva-Dimitrova</surname><given-names>D</given-names></name><name><surname>Nedialkov</surname><given-names>P</given-names></name><name><surname>Girreser</surname><given-names>U</given-names></name><name><surname>Kitanov</surname><given-names>G</given-names></name></person-group><article-title>Cytotoxic effects of hyperatomarin, a prenylated phloroglucinol from Hypericum annulatum Moris subsp. annulatum, in a panel of malignant cell lines</article-title><source>Phytomedicine.</source><year>2008</year><volume>15</volume><issue>11</issue><fpage>1010</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2008.04.008</pub-id><?supplied-pmid 18539018?><pub-id pub-id-type="pmid">18539018</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Schempp CM, Kirkin V, Simon-Haarhaus B, Kersten A, Kiss J, Termeer CC, et al. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John&#x02019;s wort that acts by induction of apoptosis. Oncogene. 2002;21(8):1242&#x02013;50. 10.1038/sj.onc.1205190.</mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ercan</surname><given-names>FS</given-names></name><name><surname>Azarkan</surname><given-names>SY</given-names></name><name><surname>Ercan</surname><given-names>N</given-names></name><name><surname>Koc</surname><given-names>M</given-names></name></person-group><article-title>Sequence variants of CYP345a1 and CYP6a14 gene regions in Tribolium castaneum (Coleoptera: Tenebrionidae) adults treated with the novel character&#x00131;zed Bolanthus turcicus (Caryophyllaceae) extract</article-title><source>Mol Biol Res Commun</source><year>2020</year><volume>9</volume><issue>3</issue><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.22099/mbrc.2020.35861.1472</pub-id><?supplied-pmid 33313329?><pub-id pub-id-type="pmid">33313329</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodossiou</surname><given-names>TA</given-names></name><name><surname>Hothersall</surname><given-names>JS</given-names></name><name><surname>De Witte</surname><given-names>PA</given-names></name><name><surname>Pantos</surname><given-names>A</given-names></name><name><surname>Agostinis</surname><given-names>P</given-names></name></person-group><article-title>The multifaceted photocytotoxic profile of hypericin</article-title><source>Mol Pharm</source><year>2009</year><volume>6</volume><issue>6</issue><fpage>1775</fpage><lpage>1789</lpage><pub-id pub-id-type="doi">10.1021/mp900166q</pub-id><?supplied-pmid 19739671?><pub-id pub-id-type="pmid">19739671</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Horby</surname><given-names>PW</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name></person-group><article-title>A novel coronavirus outbreak of global health concern</article-title><source>Lancet.</source><year>2020</year><volume>395</volume><issue>10223</issue><fpage>470</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30185-9</pub-id><?supplied-pmid 31986257?><pub-id pub-id-type="pmid">31986257</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">McConkey BJ, Sobolev V, Edelman M. The performance of current methods in ligand&#x02013;protein docking. <italic>Curr Sci</italic>. 2002:845&#x02013;56. 10.2307/24107087.</mixed-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelli</surname><given-names>I</given-names></name><name><surname>Hassani</surname><given-names>F</given-names></name><name><surname>Bekkel Brikci</surname><given-names>S</given-names></name><name><surname>Ghalem</surname><given-names>S</given-names></name></person-group><article-title><italic>In silico</italic> study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by <italic>Ammoides verticillata</italic> components harvested from Western Algeria</article-title><source>J Biomol Struct Dyn</source><year>2020</year><volume>14</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1763199</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Cui</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Niu</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Dong</surname><given-names>E</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Zhan</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name></person-group><article-title>In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</article-title><source>Clin Infect Dis</source><year>2020</year><volume>71</volume><issue>15</issue><fpage>732</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id><?supplied-pmid 32150618?><pub-id pub-id-type="pmid">32150618</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>J</given-names></name><name><surname>Jeon</surname><given-names>S</given-names></name><name><surname>Shin</surname><given-names>HY</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Seong</surname><given-names>YM</given-names></name><name><surname>Lee</surname><given-names>WJ</given-names></name><name><surname>Choe</surname><given-names>KW</given-names></name><name><surname>Kang</surname><given-names>YM</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name></person-group><article-title>Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR</article-title><source>J Korean Med Sci</source><year>2020</year><volume>35</volume><issue>6</issue><fpage>e79</fpage><pub-id pub-id-type="doi">10.3346/jkms.2020.35.e79</pub-id><?supplied-pmid 32056407?><pub-id pub-id-type="pmid">32056407</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devaux</surname><given-names>CA</given-names></name><name><surname>Rolain</surname><given-names>JM</given-names></name><name><surname>Colson</surname><given-names>P</given-names></name><name><surname>Raoult</surname><given-names>D</given-names></name></person-group><article-title>New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>55</volume><issue>5</issue><fpage>105938</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105938</pub-id><?supplied-pmid 32171740?><pub-id pub-id-type="pmid">32171740</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trott</surname><given-names>O</given-names></name><name><surname>Olson</surname><given-names>AJ</given-names></name></person-group><article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title><source>J Comput Chem</source><year>2010</year><volume>31</volume><issue>2</issue><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id><?supplied-pmid 3041641?><pub-id pub-id-type="pmid">19499576</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289&#x02013;293. 10.1038/s41586-020-2223-y.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>R</given-names></name><name><surname>Christensen</surname><given-names>MH</given-names></name></person-group><article-title>MolDock: a new technique for high-accuracy molecular docking</article-title><source>J Med Chem</source><year>2006</year><volume>49</volume><issue>11</issue><fpage>3315</fpage><lpage>3321</lpage><pub-id pub-id-type="doi">10.1021/jm051197e</pub-id><?supplied-pmid 16722650?><pub-id pub-id-type="pmid">16722650</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Yalcin S, Sas EB, Cankaya N, Ercan F, Kurt M. The physical studies and interaction with anti-apoptotic proteins of 2-(bis (cyanomethyl) amino)-2-oxoethyl methacrylate molecule. <italic>arXiv preprint arXiv:1910.00900</italic>. 2019, DOI: 10.5488/CMP.22.33301</mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Ntie-Kang F, Lifongo LL, Mbah JA, Owono Owono LC, Megnassan E, Mbaze LM, Judson PN, Sippl W, Efange SM. In silico drug metabolism and pharmacokinetic profiles of natural products from medicinal plants in the Congo basin. In Silico Pharmacol 2013;1:12. doi: 10.1186/2193-9616-1-12.</mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoete</surname><given-names>V</given-names></name><name><surname>Daina</surname><given-names>A</given-names></name><name><surname>Bovigny</surname><given-names>C</given-names></name><name><surname>Michielin</surname><given-names>O</given-names></name></person-group><article-title>SwissSimilarity: a web tool for low to ultra high throughput ligand-based virtual screening</article-title><source>J Chem Inf Model</source><year>2016</year><volume>56</volume><issue>8</issue><fpage>1399</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.6b00174</pub-id><?supplied-pmid 27391578?><pub-id pub-id-type="pmid">27391578</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daina</surname><given-names>A</given-names></name><name><surname>Michielin</surname><given-names>O</given-names></name><name><surname>Zoete</surname><given-names>V</given-names></name></person-group><article-title>SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>42717</fpage><pub-id pub-id-type="doi">10.1038/srep42717</pub-id><?supplied-pmid 28256516?><pub-id pub-id-type="pmid">28256516</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>PW</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name></person-group><article-title>admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties</article-title><source>J Chem Inf Model</source><year>2012</year><volume>52</volume><issue>11</issue><fpage>3099</fpage><lpage>3105</lpage><pub-id pub-id-type="doi">10.1021/ci300367a</pub-id><?supplied-pmid 23092397?><pub-id pub-id-type="pmid">23092397</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>CA</given-names></name><name><surname>Lombardo</surname><given-names>F</given-names></name><name><surname>Dominy</surname><given-names>BW</given-names></name><name><surname>Feeney</surname><given-names>PJ</given-names></name></person-group><article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title><source>Adv Drug Deliv Rev</source><year>2001</year><volume>46</volume><issue>1-3</issue><fpage>3</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/s0169-409x(00)00129-0</pub-id><?supplied-pmid 11259830?><pub-id pub-id-type="pmid">11259830</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veber</surname><given-names>DF</given-names></name><name><surname>Johnson</surname><given-names>SR</given-names></name><name><surname>Cheng</surname><given-names>HY</given-names></name><name><surname>Smith</surname><given-names>BR</given-names></name><name><surname>Ward</surname><given-names>KW</given-names></name><name><surname>Kopple</surname><given-names>KD</given-names></name></person-group><article-title>Molecular properties that influence the oral bioavailability of drug candidates</article-title><source>J Med Chem</source><year>2002</year><volume>45</volume><issue>12</issue><fpage>2615</fpage><lpage>2623</lpage><pub-id pub-id-type="doi">10.1021/jm020017n</pub-id><?supplied-pmid 12036371?><pub-id pub-id-type="pmid">12036371</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghose</surname><given-names>AK</given-names></name><name><surname>Viswanadhan</surname><given-names>VN</given-names></name><name><surname>Wendoloski</surname><given-names>JJ</given-names></name></person-group><article-title>A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases</article-title><source>J Comb Chem</source><year>1999</year><volume>1</volume><issue>1</issue><fpage>55</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1021/cc9800071</pub-id><?supplied-pmid 10746014?><pub-id pub-id-type="pmid">10746014</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Turner JV, Agatonovic-Kustrin S. In book: Comprehensive Medicinal Chemistry II. 2007; DOI: 10.1016/B0-08-045044-X/00147-4</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>MQ</given-names></name><name><surname>Wilkinson</surname><given-names>B</given-names></name></person-group><article-title>Drug discovery beyond the &#x02018;rule-of-five&#x02019;</article-title><source>Curr Opin Biotechnol</source><year>2007</year><volume>18</volume><issue>6</issue><fpage>478</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2007.10.005</pub-id><?supplied-pmid 18035532?><pub-id pub-id-type="pmid">18035532</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yalcin</surname><given-names>S</given-names></name></person-group><article-title>Molecular Docking, Drug Likeness, and ADMET Analyses of Passiflora compounds as P-glycoprotein (P-gp) inhibitor for the treatment of cancer</article-title><source>Curr Pharmacol Rep</source><year>2020</year><volume>6</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s40495-020-00241-6</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>CY</given-names></name><name><surname>Mu</surname><given-names>Q</given-names></name><name><surname>Gibbons</surname><given-names>S</given-names></name></person-group><article-title>The phytochemistry and pharmacology of Hypericum</article-title><source>Prog Chem Org Nat Prod</source><year>2020</year><volume>112</volume><fpage>85</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-52966-6_2</pub-id><?supplied-pmid 33306173?><pub-id pub-id-type="pmid">33306173</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Kennelly</surname><given-names>EJ</given-names></name><name><surname>Long</surname><given-names>C</given-names></name></person-group><article-title>Ethnopharmacology of Hypericum species in China: a comprehensive review on ethnobotany, phytochemistry and pharmacology</article-title><source>J Ethnopharmacol</source><year>2020</year><volume>254</volume><fpage>112686</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2020.112686</pub-id><?supplied-pmid 32101776?><pub-id pub-id-type="pmid">32101776</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allegra</surname><given-names>A</given-names></name><name><surname>Tonacci</surname><given-names>A</given-names></name><name><surname>Spagnolo</surname><given-names>EV</given-names></name><name><surname>Musolino</surname><given-names>C</given-names></name><name><surname>Gangemi</surname><given-names>S</given-names></name></person-group><article-title>Antiproliferative effects of St. John&#x02019;s wort, its derivatives, and other Hypericum species in hematologic malignancies</article-title><source>Int J Mol Sci</source><year>2020</year><volume>22</volume><issue>1</issue><fpage>146</fpage><pub-id pub-id-type="doi">10.3390/ijms22010146</pub-id></element-citation></ref></ref-list></back></article>